The first clinical trial that investigated the combination of APR-246 and AZA was a U.S. phase II trial [102,136] (NCT03072043) in which there were 55 patients with TP53 mutation (40 MDS and 11 AML) with a median age of 66 years enrolled. The gene discussed is TP53; the disease is acute myeloid leukemia.